Agenus (AGEN) Projected to Release Earnings on Thursday

Agenus (NASDAQ:AGEN) is projected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Agenus to post earnings of $0.05 per share and revenue of $34.00 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 7:30 AM ET.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. The business had revenue of $33.74 million for the quarter, compared to the consensus estimate of $129.50 million. On average, analysts expect Agenus to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Agenus Trading Up 4.8%

Agenus stock opened at $8.20 on Wednesday. Agenus has a 1-year low of $2.71 and a 1-year high of $8.70. The firm has a market capitalization of $366.73 million, a price-to-earnings ratio of 5.15 and a beta of 1.41. The firm’s fifty day moving average price is $4.24 and its two-hundred day moving average price is $3.73.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AGEN shares. HC Wainwright raised their price target on shares of Agenus from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d)” rating on shares of Agenus in a report on Tuesday, June 16th. Finally, B. Riley Financial reiterated a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agenus has a consensus rating of “Hold” and a consensus target price of $22.00.

Institutional Investors Weigh In On Agenus

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. LPL Financial LLC boosted its stake in shares of Agenus by 20.3% in the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock worth $73,000 after buying an additional 3,943 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Agenus during the fourth quarter valued at approximately $31,000. Jump Financial LLC bought a new stake in Agenus during the second quarter worth $55,000. Squarepoint Ops LLC purchased a new position in Agenus in the third quarter worth $54,000. Finally, Tower Research Capital LLC TRC grew its stake in Agenus by 265.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 21,871 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 15,893 shares during the period. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.